Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drug could shield kidneys in rare disease

NCT ID NCT06090227

First seen Feb 03, 2026 · Last updated May 25, 2026 · Updated 16 times

Summary

This study tests whether the diabetes drug metformin can protect kidney cells in people with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. About 30 adults will take either extended-release metformin or a placebo for 6 months, alongside their usual treatments. The goal is to see if metformin reduces kidney cell damage and helps preserve kidney function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact

  • Yale New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.